EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Effects of Atorvastatin on Atherosclerosis and Atherogenesis in Systemic Lupus Erythematosus: A Pilot Study

Katharina Benita Sokoll, Joana Batuca, Luis Romulo Lopez, Elizabeth Hensor, Paul Emery, José Delgado Alves, Paul Richard Julian Ames

ISRN Immunology · 2014

DOI: 10.1155/2014/295239 ↗
AbstractBibliografische Angaben

Abstract

Objective . The effect of statins on atherogenesis in systemic lupus erythematosus (SLE) is poorly known. To inform a wider trial we performed a pilot study evaluating the intima-media thickness of the common carotid artery (CIMT) and some oxidative [beta-2-glycoprotein-1 complexed with oxidised low density lipoprotein ( β 2 GPIoxLDL)], metabolic [paraoxonase (PON), nitrate ( NO 3 − ), nitrite ( NO 2 − ) and nitrotyrosine (NT)], inflammatory [C-reactive protein (CRP) and serum amyloid A (SAA)], and lipid markers before and after 1 year of treatment with 40 mg of oral atorvastatin (AT). Methods . Randomised, double blind, placebo controlled pilot study on consecutive SLE patients: 17 SLE patients were randomised into the AT arm and 20 into the placebo arm. CIMT was measured by high-resolution sonography, PONa by a spectrophotometric method, NO 3 − and NO 2 − by a colorimetric assay and oxLDL- β 2 GPI, NT, CRP, and SAA by Elisa. Results . After correction for age and disease duration oxLDL- β 2 GPI decreased by 27% ( P = 0.002 ) and PON/HDL ratio increased by 12% ( P = 0.01 ) but CIMT did not change. Conclusion . This pilot study revealed a decrease of oxLDL- β 2 GPI (oxidant marker) and an increase of PON/HDL ratio (antioxidant activity) after AT indicating a favourable effect of the drug on atherogenic pathways that should be explored on larger trials.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →